AF
DNLI icon

Amalgamated Financial’s Denali Therapeutics DNLI Stock Holding History

Amalgamated Financial’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$479K Buy
+14,893
New +$512K ﹤0.01% 1530

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Amalgamated Financial's DNLI Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Denali Therapeutics (DNLI) in Q1 2022: 14,893 shares worth $479K. The stake represents ﹤0.01% of the portfolio and ranks #1530 among its holdings.

190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Amalgamated Financial held 14,893 shares of Denali Therapeutics worth $479K as of Q1 2022.
  • Denali Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Denali Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1530 holding.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.